140 related articles for article (PubMed ID: 36077736)
1. A Pan-Cancer Assessment of
Cai L; DeBerardinis RJ; Xiao G; Minna JD; Xie Y
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077736
[TBL] [Abstract][Full Text] [Related]
2. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of TP-53/Rb-1 Co-Mutation in Large Cell Neuroendocrine Carcinoma.
Saghaeiannejad Esfahani H; Vela CM; Chauhan A
Front Oncol; 2021; 11():653153. PubMed ID: 34141612
[TBL] [Abstract][Full Text] [Related]
4. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
5. Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile.
Astolfi A; Nannini M; Indio V; Schipani A; Rizzo A; Perrone AM; De Iaco P; Pirini MG; De Leo A; Urbini M; Secchiero P; Pantaleo MA
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751892
[TBL] [Abstract][Full Text] [Related]
6. Next-generation sequencing of salivary high-grade neuroendocrine carcinomas identifies alterations in RB1 and the mTOR pathway.
Goyal B; Duncavage EJ; Martinez D; Lewis JS; Chernock RD
Exp Mol Pathol; 2014 Dec; 97(3):572-8. PubMed ID: 25446844
[TBL] [Abstract][Full Text] [Related]
7. RB1 and TP53 pathways in radiation-induced sarcomas.
Gonin-Laurent N; Hadj-Hamou NS; Vogt N; Houdayer C; Gauthiers-Villars M; Dehainault C; Sastre-Garau X; Chevillard S; Malfoy B
Oncogene; 2007 Sep; 26(41):6106-12. PubMed ID: 17369843
[TBL] [Abstract][Full Text] [Related]
8. Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation.
Harms PW; Collie AM; Hovelson DH; Cani AK; Verhaegen ME; Patel RM; Fullen DR; Omata K; Dlugosz AA; Tomlins SA; Billings SD
Mod Pathol; 2016 Mar; 29(3):240-8. PubMed ID: 26743471
[TBL] [Abstract][Full Text] [Related]
9. Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta-analysis.
Chen J; Shi M; Chuen Choi SY; Wang Y; Lin D; Zeng H; Wang Y
BJUI Compass; 2023 May; 4(3):256-265. PubMed ID: 37025467
[TBL] [Abstract][Full Text] [Related]
10. Landscape of
Xu G; Zheng J; Wang S; Wang Y; Li G; Wang N; She X; Duan W; Zhang H; Huang D; Bei T; Fu D; Yang J
Ann Transl Med; 2022 Aug; 10(16):885. PubMed ID: 36110997
[TBL] [Abstract][Full Text] [Related]
11. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract.
Wu H; Yu Z; Liu Y; Guo L; Teng L; Guo L; Liang L; Wang J; Gao J; Li R; Yang L; Nie X; Su D; Liang Z
Cancer Commun (Lond); 2022 Dec; 42(12):1367-1386. PubMed ID: 36264285
[TBL] [Abstract][Full Text] [Related]
12. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
[TBL] [Abstract][Full Text] [Related]
13. Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients.
Tao Z; Li T; Feng Z; Liu C; Shao Y; Zhu M; Gong C; Wang B; Cao J; Wang L; Du Y; Lizaso A; Li B; Zhang J; Hu X
Front Oncol; 2020; 10():1023. PubMed ID: 32695676
[No Abstract] [Full Text] [Related]
14. Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors.
Merten L; Agaimy A; Moskalev EA; Giedl J; Kayser C; Geddert H; Schaefer IM; Cameron S; Werner M; Ströbel P; Hartmann A; Haller F
Am J Clin Pathol; 2016 Dec; 146(6):718-726. PubMed ID: 28028119
[TBL] [Abstract][Full Text] [Related]
15. Genomic characterization of small cell carcinomas of the uterine cervix.
Schultheis AM; de Bruijn I; Selenica P; Macedo GS; da Silva EM; Piscuoglio S; Jungbluth AA; Park KJ; Klimstra DS; Wardelmann E; Hartmann W; Gerharz CD; von Petersdorff M; Buettner R; Reis-Filho JS; Weigelt B
Mol Oncol; 2022 Feb; 16(4):833-845. PubMed ID: 33830625
[TBL] [Abstract][Full Text] [Related]
16. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; ; Ruland A; Speel EJM; Dingemans AMC
Lung Cancer; 2019 Dec; 138():102-108. PubMed ID: 31678831
[TBL] [Abstract][Full Text] [Related]
17. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.
Goh G; Walradt T; Markarov V; Blom A; Riaz N; Doumani R; Stafstrom K; Moshiri A; Yelistratova L; Levinsohn J; Chan TA; Nghiem P; Lifton RP; Choi J
Oncotarget; 2016 Jan; 7(3):3403-15. PubMed ID: 26655088
[TBL] [Abstract][Full Text] [Related]
18. High-grade transformation of pancreatic neuroendocrine tumor associated with TP53 mutations: A diagnostic pitfall mimicking neuroendocrine carcinoma.
Tanaka M; Shinozaki-Ushiku A; Kunita A; Yasunaga Y; Akamatsu N; Hasegawa K; Ushiku T
Pathol Int; 2022 Aug; 72(8):411-418. PubMed ID: 35698921
[TBL] [Abstract][Full Text] [Related]
19. TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia.
Hara Y; Shiba N; Yoshida K; Yamato G; Kaburagi T; Shiraishi Y; Ohki K; Shiozawa Y; Kawamura M; Kawasaki H; Sotomatsu M; Takizawa T; Matsuo H; Shimada A; Kiyokawa N; Tomizawa D; Taga T; Ito E; Horibe K; Miyano S; Adachi S; Taki T; Ogawa S; Hayashi Y
Genes Chromosomes Cancer; 2023 Jul; 62(7):412-422. PubMed ID: 37102302
[TBL] [Abstract][Full Text] [Related]
20. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
Nyquist MD; Corella A; Coleman I; De Sarkar N; Kaipainen A; Ha G; Gulati R; Ang L; Chatterjee P; Lucas J; Pritchard C; Risbridger G; Isaacs J; Montgomery B; Morrissey C; Corey E; Nelson PS
Cell Rep; 2020 May; 31(8):107669. PubMed ID: 32460015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]